Cambridge, Mass. – May 15, 2019 – Biogen (Nasdaq: BIIB) today announced it will host a live webcast and Q&A session to review its portfolio of investigational therapies for the treatment of amyotrophic lateral sclerosis (ALS). The live webcast will begin at 8:00 a.m. ET with Hani Houshyar, Ph.D., senior director and product development and commercialization lead for tofersen (BIIB067), Wildon Farwell, M.D., executive medical director, clinical development, and Chris Henderson, Ph.D., vice president and head of neuromuscular and movement disorders research unit. Additionally, Michael Ehlers, M.D., Ph.D., executive vice president, research and development, will be available for Q&A. To access the live webcast, please go to the investors section of Biogen’s website at www.biogen.com/investors. Following the live webcast, an archived version of the call will be available on the website.
About Biogen
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip Sharp, and today has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is focused on advancing neuroscience research programs in MS and neuroimmunology, Alzheimer’s disease and dementia, movement disorders, neuromuscular disorders, acute neurology, neurocognitive disorders, pain, and ophthalmology. Biogen also commercializes biosimilars of advanced biologics.
We routinely post information that may be important to investors on our website at www.biogen.com. To learn more, please visit www.biogen.com and follow us on social media – Twitter, LinkedIn, Facebook, YouTube.
###
| MEDIA CONTACT: David Caouette +1 617 679 4945 public.affairs@biogen.com |
INVESTOR CONTACT: Matt Calistri +1 781 464 2442 IR@biogen.com |
